Company Overview	9 Months Ended
Sep. 30, 2011
Company Overview	Note 1 – Company Overview Neogenix Oncology, Inc. (“Neogenix” or the “Company”) was formed as a Maryland corporation in 2003 and rents research and development facilities in Rockville, Maryland and Great Neck, New York and has its administrative and clinical studies offices in Rockville, Maryland. The Company is a biotechnology company focused on developing novel therapeutic and diagnostic products for the treatment and detection of cancer. Neogenix has not commenced its planned or principal operations and has not generated any revenues since its inception, and as such is considered a development stage enterprise. The products being developed will require substantial funding to further research and development, clinical testing, and regulatory approval prior to their commercialization. The Company has devoted initial efforts primarily towards the development of therapeutic monoclonal antibodies, targeted against pancreatic and colorectal cancer. Human clinical studies are ongoing to establish safety and dosing parameters for its first therapeutic drug. The Company has obtained “Orphan Drug” status from the U.S. Food and Drug Administration (the “FDA”) for its pancreatic cancer therapeutic drug candidate. The Company has also devoted efforts towards the research and development of diagnostic tests for the detection of pancreatic and colon cancer. The Company's diagnostic tests are expected to serve as “companion diagnostics” for its therapeutic drug and also have the potential to serve as standalone tests for the diagnosis and detection of cancer. Such independent diagnostic tests will require FDA regulatory approval.

Company Overview

9 Months Ended

Sep. 30, 2011

Note 1 – Company Overview

Neogenix Oncology, Inc. (“Neogenix” or the “Company”) was formed as a Maryland corporation in 2003 and rents research and development facilities in Rockville, Maryland and Great Neck, New York and has its administrative and clinical studies offices in Rockville, Maryland. The Company is a biotechnology company focused on developing novel therapeutic and diagnostic products for the treatment and detection of cancer. Neogenix has not commenced its planned or principal operations and has not generated any revenues since its inception, and as such is considered a development stage enterprise. The products being developed will require substantial funding to further research and development, clinical testing, and regulatory approval prior to their commercialization.

The Company has devoted initial efforts primarily towards the development of therapeutic monoclonal antibodies, targeted against pancreatic and colorectal cancer. Human clinical studies are ongoing to establish safety and dosing parameters for its first therapeutic drug. The Company has obtained “Orphan Drug” status from the U.S. Food and Drug Administration (the “FDA”) for its pancreatic cancer therapeutic drug candidate.

The Company has also devoted efforts towards the research and development of diagnostic tests for the detection of pancreatic and colon cancer. The Company's diagnostic tests are expected to serve as “companion diagnostics” for its therapeutic drug and also have the potential to serve as standalone tests for the diagnosis and detection of cancer. Such independent diagnostic tests will require FDA regulatory approval.

Neogenix Oncology Inc 10-Q